A Phase II Single-arm Trial of BIBW 2992 in Demographically and Genotypically Selected NSCLC.

Trial Profile

A Phase II Single-arm Trial of BIBW 2992 in Demographically and Genotypically Selected NSCLC.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Afatinib (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 08 Feb 2012 Actual patient number 41 added as reported by ClinicalTrials.gov.
    • 08 Feb 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
    • 08 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top